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Transparency: A Fundamental
Social Obligation for Clinical
Research
After 60 years devoted to enhancing the
methodology and ethics in clinical re-
search, the last decade has been crucial
to the scientific community in refining the
transparency on conducting clinical trials
(CTs), from their inception to the publi-
cation of results. A myriad of articles have
been published on the design, conduct,
conflicts of interest, reporting, and publi-
cation of CTs. Now a responsible investi-
gator (or sponsor) involved in the design
and conduct of a CT must, in addition to
obtaining research ethics committee
(REC) and, in many countries, regulatory
approvals, register the protocol in a
publicly accessible registry before recruit-
ing the first participant and publish (or
otherwise make publicly available) the
results obtained [1–4]. There are many
CT registries, 14 of which are included on
the WHO International Clinical Trials
Registry Platform [5]. ClinicalTrials.gov
[6], the largest with more than 90,000 CTs
from around the world, provides a sub-
stantial amount of information to anybody
interested in a trial. However, an impor-
tant piece of information is lacking:
recruitment information for each site
participating in the CT. We believe in
the benefits of increased transparency in
all phases of clinical research, since it has
been proven not only to build trust, but
also to be one of the best tools to reduce
bias, to improve credibility of the results,
and to foster the efficient management of
trials.
Recruitment: A Crucial Aspect in
Conducting a Clinical Trial
A critical aspect to carefully consider in
the planning of a CT is the number of
participants to be recruited in a specified
time period and to outline contingency
plans if problems in recruitment arise. It is
well known that recruiting participants can
be a significant burden and is frequently
the most difficult task in conducting a CT.
Failure to reach the planned sample size
within the agreed time frame and funding
is common. Poor recruitment is a waste of
resources and a potential abuse of partic-
ipant goodwill. In the UK, only 31% of
CTs sponsored by the Medical Research
Council and the Health Technology
Assessment Programme achieved their
original recruitment target; furthermore,
55% did not reach the revised target [7].
In 333 concluded UK public and charity-
sponsored cancer trials that were started
between 1971 and 2000, only 48%
reached the planned sample size, whereas
20% of the CTs recruited less than 25% of
the planned sample size [8]. Recent US
data showed that among 180 National
Cancer Institute (NCI) Cancer Evaluation
Program-sponsored CTs, activated be-
tween 2000 to 2004 and closed to accrual,
36% and 62% of phase 2 and 3 trials,
respectively, did not attain their recruit-
ment goals [9].
This pattern in publicly funded trials is
also occurring in industry-sponsored trials.
For example, in an industry-sponsored
multicenter clinical trial (MCT) on asthma
conducted in 11 countries, only 35% of
sites succeeded (or exceeded) in recruiting
the committed number of patients [10]. In
fact, some companies assume in the
planning phase that up to 25% of the sites
in a MCT will never enroll a single patient
[11], which emphasizes the difficulty of
recruiting participants. Reports from
RECs also found a significant percentage
of CTs with poor recruitment [12–14].
Overestimating the pool of eligible pa-
tients or the recruitment rate (known as
‘‘Lasagna’s law’’) occurs even though
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Good Clinical Practice guidelines state
that investigators ‘‘should be able to
demonstrate (e.g., based on retrospective
data) a potential for recruiting the required
number of suitable subjects within the
agreed recruitment period,’’ and that ‘‘the
investigator should have sufficient time to
properly conduct and complete the trial
within the agreed trial period’’ [15].
Recently a number of reviews on inter-
ventions to improve CT recruitment have
been published [16,17].
Except for some early proof-of-concept
CTs, a sample size estimation should be
conducted and reported in the trial
protocol for all randomized CTs—some-
thing that is frequently lacking [18,19]—
or a rationale for not doing so should be
included in the study protocol. Data show
that in up to 66% [19] to 75% [20] of CT
reports, there is no reporting of the sample
size estimation.
In planning a CT, sample size estima-
tion will trigger many decisions about the
number of recruitment sites (and even
countries) required to successfully accrue
participants. If the number of participants
is such that the research question cannot
be properly answered, the trial may risk
becoming scientifically useless and ethical-
ly unacceptable: the CT will bring burdens
and risks (e.g., adverse effects) to partici-
pants, with no medical benefit for future
patients because of its lack of scientific
usefulness (e.g., no statistically significant
difference detected between treatment
groups). The question that follows is: what
about the many CTs that never recruit the
number of participants needed to appro-
priately test the underlying hypothesis? Is
this not a (subtle) way of not fulfilling the
investigator–participant contract inherent
in a CT? If the results are not published in
peer-reviewed journals, the investigator or
the sponsor should make the results
available through a private registry (e.g.,
company website) and provide a link to the
website through a public registry (e.g.,
ClinicalTrials.gov). If the obligation to
making the results publicly available is
fulfilled, a CT that has not recruited the
number of participants needed is under-
powered and less informative from the
perspective of the individual CT; none-
theless, the data, may be of scientific use if
they are used to conduct meta-analyses.
The Proposal: To Provide
Information on All Site Principal
Investigators’ Recruitment
Performance
Recruitment performance of clinical
centers and investigators varies significant-
ly [10], in both public- and private-
sponsored CTs, although most drug
MCTs are sponsored by industry [21].
Many investigators will participate in a
number of trials in their professional
careers, sometimes even simultaneously
for the same condition. Through public
registries, such as ClinicalTrials.gov, ac-
cess to information is made available on
the scientific rationale, methods, sponsor-
ship, scientific leadership, calendar, con-
tacts, and locations. Although currently
available CT registration enhances trans-
parency, deficiencies have been found that
undermine the full potential usefulness of
registries [22]. We believe that recruiting
sites’ principal investigators should be
accountable for the conduct and outcome
of their trial. This should be regarded
similarly to the current practice of pub-
lishing MCT results in a manuscript with
all recruiting researchers included as
members of the ‘‘study group.’’ Hence,
we propose not only to disclose the names,
contact details, and affiliations of all sites’
recruiting investigators in the registry
before trial start, something that is cur-
rently being provided by a variety of
sponsors [6], but also to reveal their
recruitment commitment and the number
of recruited participants (Table 1).
It should be highlighted that some
sponsors do currently provide information
on the recruitment status of all sites
involved in an MCT. Thus, in Clinical-
Trials.gov [6], near the site principal
investigator contact details, the recruit-
ment status is sometimes provided as ‘‘not
yet recruiting,’’ ‘‘active, but not recruit-
ing,’’ ‘‘recruiting,’’ ‘‘completed,’’ or ‘‘with-
drawn’’. We propose for a given site, that
if the trial has more than one recruiting
principal investigator, then information for
all recruiting investigators should be pro-
vided. This information will allow readers
to assess the performance of each site
principal investigator. This information
may be of interest to the REC (or
institutional review board) assessing the
qualifications of a given researcher (and
CT underway or committed in the same
population) when reviewing a CT protocol
[15], and to patient organizations, hospital
and university managers, CT networks
and collaborative groups, public and
private sponsors, and health authorities.
Thus, sponsors willing to start a CT may
wish to recruit investigators with a track
record of fulfilling their commitments,
hospital or university managers may want
data on the performance of their investi-
gators in an activity that can impact their
institutions’ prestige, and patient organi-
zations may want to know the investigators
who actually recruit most participants in
CTs in their area of interest. Furthermore,
since it is well known that both ethnic and
standard-of-care differences can impact
treatment outcomes in different geograph-
ical regions [23–25], having access to the
percentage of participants coming from
different countries (and, hence, regions)
could prompt queries to the sponsor from
experts about regional subgroup analyses.
In addition, providing recruitment data
could be of interest to researchers con-
ducting prospective meta-analysis and
individual patient data meta-analysis to
examine specific outcomes and harms.
Participants in a trial have the right to be
informed on the results obtained [3]: if an
MCT is not concluded because of recruit-
ment issues, recruiting site principal inves-
tigators could transparently inform trial
participants wishing to know which cen-
ters did not deliver as expected, because
the data are available on the registry.
Finally, misconduct and fraud in clinical
Summary Points
N Many clinical trials are terminated before reaching the sample size needed to
test the trials’ hypotheses owing to poor recruitment.
N Registries, such as ClinicalTrials.gov, provide information on the main features of a
multicenter clinical trial (MCT) to the general public.
N Site investigators are key to the success of MCTs; however, information on their
recruitment performance is not publicly available.
N We propose that sponsors should disclose the recruitment targets of all site
investigators on ClinicalTrials.gov before a trial starts as well as their final
recruitment. Information on issues that could have affected recruitment should
also be provided.
N This information will be of interest to different stakeholders such as patient
organizations, sponsors, and MCT networks.
N Disclosing all site investigators’ recruitment figures could prompt queries to the
sponsor from the scientific community about regional subgroup analyses, to assess if
ethnic or standard-of-care differences have an impact on treatment outcomes.
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research does happen [26,27]. Full trans-
parency regarding recruitment goals and
results should help to reduce the risk of
misconduct and fraud.
How to Comply with the
Proposal: The Practicalities
Registering investigators’ recruitment
performance information in MCTs should
be straightforward, since a record of all
research sites is always regularly up-dated
(on a real-time enrollment basis in many
trials) by the sponsor or the coordinating
center. Hence, this proposal represents a
modest burden on sponsors. It is reason-
able to believe that the fact of having these
data publicly disclosed will encourage site
recruiting investigators to ask the sponsor
to update the information; at the end of
the day, each investigator should take
responsibility for his/her own reputation
in relation to patients, institution, and
other researchers. At the very least, the
recruitment final data per site principal
investigator should be provided when
recruitment of participants has been con-
cluded (having achieved or not achieved
the trial’s target number of participants).
In any case, information regarding re-
cruitment per site is usually included in the
MCT final report and when reporting
industry-sponsored trials results to regula-
tory agencies [28].
Importantly, once the initial list of
recruiting centers and site principal inves-
tigators (and, following our proposal, their
recruitment targets) is provided, the list
will not usually change unless (a) an
investigator is asked to stop his/her con-
tribution to the trial because of a lack of
recruitment; in this case, the sponsor
should include the appropriate informa-
tion on the registry, or (b) new recruiting
centers or investigators are added to the
original list, most likely as a contingency
plan to enhance the trial’s poor recruiting
rate to date. After the initial target
between the sponsor and each site inves-
tigator is agreed upon, further agreements
should be registered; a record of these
agreements will be available on the
registry’s archive site thanks to the audit
trail [6].
Any related issue that could affect
recruitment in a site should be disclosed,
thus providing the reader with the neces-
sary information to understand what
happened during the recruitment period
of the trial. Among the non-site investiga-
tor related issues, and to facilitate submis-
sion of information, we propose that this
information should be classified in a
number of ‘‘closed’’ reasons, as shown in
Table 1. Similarly, any unexpected inves-
tigator-related reason that could impact
his/her recruitment performance should
be recorded. We suggest only a ‘‘closed’’
reason (‘‘health issues’’) in this section.
Conclusion
Since all parties involved (from re-
search-funding agencies and regulatory
agencies to journal editors and industry)
are asking for transparency in CTs [4,29],
we propose that its level should be taken
beyond the current limits. We acknowl-
edge that several critical issues need to be
addressed in the near future to enhance
CT transparency. Among these are the
urgent need for sponsors to provide
complete and accurate information as
required by public registries [22] as well
as access to trial protocols and raw
databases [30]. In this respect, we propose
that all MCTs registered in publicly
available registries, such as ClinicalTrials.-
gov [6], should provide detailed informa-
tion about the names, contact details,
recruitment commitments, and recruit-
ment deliveries of all site principal inves-
tigators involved. This information will
Table 1. Key elements of principal investigators at each recruiting site involved in multicenter clinical trials to be disclosed in a
publicly open clinical trial registry such as ClinicalTrials.gov.
Element Description
1. Name, contact details (e.g., email address, phone), and affiliation (department,
institution, city, country)a
—
2. Site recruitment status: ‘‘not yet recruiting,’’ ‘‘active, but not recruiting,’’
‘‘recruiting,’’ ‘‘completed,’’ or ‘‘withdrawn’’
—
3. Recruitment commitment: number of participants to be recruited. This figure refers to those participants who are to be randomized.
4. Actual recruitment: number of participants actually randomized. —
5. Non-investigator–related issues impacting clinical trial recruitment: Delays due to REC/institutional review board reasons
Delays due to regulatory reasons
Delays due to center–sponsor contract negotiations
Issues with sample dispatch
Halt randomization of participants included in the prerandomization periodb
Early termination of the clinical trialc
Other (specify)
6. Unexpected investigator-related issues impacting clinical trial recruitment: Health issue
Other (specify)
If there is more than one principal investigator in a site all the information should be provided on all of them.
aMultiple locations may be specified on ClinicalTrials.gov. Currently, when provided, the name (and contact details) of a contact person (not necessarily the site principal
investigator) is usually given. On the other hand, there are examples in which contact details of all site principal investigators are provided: these are multicenter
clinical trials sponsored by, for instance, nonprofit organizations (e.g., NCT01264445), governmental institutions (e.g., NCT01108614), research foundations (e.g.,
NCT00662220), industry (e.g., NCT00944905), universities (e.g., NCT00973154), collaborative groups (e.g., NCT00209209), or hospitals (e.g., NCT00756600) [6].
bDue to early achievement of the number of (randomized) participants needed in the clinical trial.
cWhen the trial is terminated, for whatever reason, before completing the expected recruitment. Currently ClinicalTrials.gov allows inclusion of information regarding
suspended, terminated, or withdrawn studies providing ‘‘a brief explanation of why the study has been halted or terminated. If desired, use brief summary or detailed
description to provide additional information. (Limit: 160 characters)’’ [6].
doi:10.1371/journal.pmed.1001149.t001
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make them accountable for the MCT
performance not only to the sponsor, but
also to all participating patients or healthy
volunteers and recruiting investigators, all
other interested researchers in the field,
and, ultimately, society as a whole. In
fact, disclosing the recruitment perfor-
mance of all site recruiting principal
investigators is a small but relevant part
of an MCT’s raw data; they must be
considered as belonging to the scientific
study information that should be openly
shared, something that is currently being
promoted by private and public funding
organizations [31]. Similar to other ini-
tiatives established to improve transpar-
ency, such as the CONSORT state-
ment—although this was enforced by
journal editors—moves by sponsors to
comply with this proposal are likely to be
gradual [32,33]. We view reporting of
site-level recruitment to be a logical next
step in improving trial transparency, and
we hope that many sponsors will help in
implementing this initiative.
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